TABLE 1.
Patient Characteristics Categorized by ECV and T2
| Global ECV |
Global T2 |
||||||
|---|---|---|---|---|---|---|---|
| ECV <25% (1st tercile) (n = 29) | ECV 25%-29% (2nd tercile) (n = 32) | ECV 29% (3rd tercile) (n = 29) | p Value | T2 <50.2 ms (T2 <median) (n = 39) | T2 ≥50.2 ms (T2 ≥median) (n = 40) | p Value | |
| Age, yrs | 50 ± 17 | 51 ± 17 | 48 ± 14 | 0.69 | 52.8 ± 15.3 | 48.9 ± 15.6 | 0.12 |
|
| |||||||
| Female | 9 (31) | 13 (41) | 11 (38) | 0.73 | 15 (39) | 17 (43) | 0.72 |
|
| |||||||
| OHT-CMR interval, yrs | 6.0 (3.5–8.3) | 5.5 (3.0–8.0) | 3.7 (0.5–7.6) | 0.20 | 6.3 (3.9–9.1) | 6.1 (4.0–8.6) | 0.12 |
|
| |||||||
| Any CAV | 11 (39) | 14 (45) | 12 (44) | 0.89 | 19 (49) | 20 (50) | 0.91 |
|
| |||||||
| Hypertension | 25 (86) | 27 (84) | 24 (83) | 0.94 | 32 (82) | 38 (95) | 0.07 |
|
| |||||||
| Dyslipidemia | 20 (69) | 17 (53) | 10 (35) | 0.03 | 24 (62) | 21 (53) | 0.42 |
|
| |||||||
| Diabetes mellitus | 11 (38) | 10 (31) | 9 (31) | 0.82 | 15 (39) | 10 (25) | 0.20 |
|
| |||||||
| History of rejection | 4(14) | 10 (31) | 6 (21) | 0.25 | 8 (21) | 12 (30) | 0.33 |
|
| |||||||
| Antimetabolite | 26 (90) | 28 (88) | 27 (93) | 0.77 | 37 (95) | 35 (88) | 0.25 |
|
| |||||||
| Antiproliferative | 28 (97) | 31 (97) | 29 (100) | 0.61 | 37 (95) | 40 (100) | 0.10 |
|
| |||||||
| Steroid | 11 (38) | 9 (28) | 16 (55) | 0.10 | 12 (31) | 10 (25) | 0.75 |
|
| |||||||
| Beta-blocker | 7(24) | 11 (34) | 6 (21) | 0.45 | 6 (15) | 16 (40) | 0.02 |
|
| |||||||
| CCB | 6 (21) | 3 (9) | 6 (21) | 0.39 | 7 (18) | 7 (18) | 0.96 |
|
| |||||||
| ARB | 3 (10) | 3 (9) | 0 (0) | 0.21 | 4 (10) | 3 (8) | 0.67 |
|
| |||||||
| ACEI | 13 (45) | 12 (38) | 14 (48) | 0.68 | 22 (56) | 20 (50) | 0.57 |
|
| |||||||
| Statin | 27 (93) | 29 (91) | 27 (93) | 0.92 | 36 (92) | 35 (89) | 0.48 |
|
| |||||||
| Antiplatelet | 27 (93) | 26 (81) | 26 (90) | 0.34 | 31 (80) | 37 (93) | 0.10 |
|
| |||||||
| Aldosterone antagonist | 4 (14) | 3 (9) | 3 (10) | 0.85 | 2 (5) | 7 (18) | 0.08 |
|
| |||||||
| Diuretic | 8 (28) | 9 (29) | 12 (41) | 0.47 | 9 (23) | 13 (33) | 0.31 |
|
| |||||||
| Presence of LGE | 11 (38) | 11 (34) | 10 (35) | 0.95 | 12 (34) | 16 (46) | 0.33 |
|
| |||||||
| LGE extent,% | 1.5 ± 2.5 | 1.4 ± 2.2 | 1.9 ± 4.6 | 0.81 | 1.3 ± 2.2 | 2.6 ± 4.4 | 0.14 |
|
| |||||||
| Global native T1 | 0.25 | 0.54 | |||||
| 1st tercile (<1,005 ms) | 12 (41) | 10 (31) | 8 (28) | 11 (31) | 15 (43) | ||
| 2nd tercile (1,005-1,056 ms) | 11 (38) | 12 (38) | 7 (24) | 15 (43) | 11 (31) | ||
| 3rd tercile (>1,056 ms) | 6 (21) | 10 (31) | 14 (48) | 9 (26) | 9 (26) | ||
|
| |||||||
| LVEF, % | 58 ± 10 | 56 ± 9 | 57 ± 7 | 0.67 | 56.6 ± 7.8 | 56.9 ± 8.8 | 0.86 |
|
| |||||||
| LVEDVI, ml/m2 | 58 ± 13 | 63 ± 19 | 66 ± 16 | 0.18 | 59.8 ± 14.4 | 61.7 ± 16.1 | 0.60 |
|
| |||||||
| LVESVI, ml/m2 | 25 ± 9 | 26 ± 12 | 28 ± 9 | 0.46 | 26.1 ± 8.8 | 25.1 ± 8.2 | 0.58 |
|
| |||||||
| LVSV, ml | 64 ± 14 | 67 ± 21 | 73 ± 20 | 0.21 | 66.6 ± 19.1 | 66.9 ± 19.4 | 0.94 |
|
| |||||||
| LVCO, ml | 5.8 ± 1.2 | 5.8 ± 1.6 | 6.3 ± 1.9 | 0.33 | 5.6 ± 1.3 | 6.0 ± 1.8 | 0.27 |
|
| |||||||
| LVMI, g/m2 | 58 ± 18 | 56 ± 14 | 59 ± 17 | 0.81 | 56.1 ± 18.1 | 52.3 ± 13.3 | 0.31 |
|
| |||||||
| RVEF, % | 51 ± 8 | 50 ± 9 | 50 ± 8 | 0.88 | 50.2 ± 7.6 | 50.0 ± 9.1 | 0.93 |
|
| |||||||
| RVEDVI, ml/m2 | 65 ± 12 | 69 ± 15 | 24 ± 5 | 0.28 | 66.8 ± 15.5 | 70.6 ± 16.0 | 0.30 |
|
| |||||||
| RVESVI, ml/m2 | 33 ± 8 | 35 ± 10 | 16 ± 3 | 0.36 | 33.1 ± 9.1 | 36.0 ± 11.9 | 0.24 |
|
| |||||||
| RHC-RAP, mm Hg | 6 ± 4 | 10 ± 7 | 10 ± 7 | 0.03 | 7.6 ± 5.4 | 8.9 ± 6.1 | 0.33 |
|
| |||||||
| RHC-RVSP, mm Hg | 28 ± 8 | 34 ± 9 | 34 ± 10 | 0.02 | 30.1 ± 8.2 | 31.2 ± 9.1 | 0.38 |
|
| |||||||
| RHC-RVDP, mm Hg | 4 ± 3* | 7 ± 6* | 7 ± 5 | 0.02 | 5.5 ± 5.1 | 6.1 ± 4.9 | 0.63 |
|
| |||||||
| RHC-PASP, mm Hg | 27 ± 8 | 32 ± 11 | 33 ± 11 | 0.05 | 28.6 ± (8.2 | 30.0 ± 10.5 | 0.52 |
|
| |||||||
| RHC-PADP, mm Hg | 12 ± 6 | 16 ± 9 | 17 ± 8 | 0.06 | 13.3 ± 5.8 | 14.3 ± 8.2 | 0.54 |
|
| |||||||
| RHC-mPAP, mm Hg | 19 ± 6* | 23 ± 9 | 24 ± 9* | 0.04 | 20.3 ± 7.1 | 21.4 ± 8.1 | 0.54 |
|
| |||||||
| RHC-PCWP, mm Hg | 11 ± 5* | 14 ± 8 | 16 ± 8* | 0.01 | 11.8 ± 5.3 | 13.6 ± 8.0 | 0.23 |
|
| |||||||
| RHC-CI, ml/m2 | 3.2 ± 0.8 | 3.0 ± 0.8 | 2.9 ± 0.9 | 0.50 | 3.1 ± 1.0 | 3.0 ± 1.0 | 0.73 |
Values are mean ± SD, n (%), or median (interquartile range).
Statistically significant with p < 0.05.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAV = cardiac allograft vasculopathy; CCB = calcium channel blocker; CI = cardiac index; ECV = extracellular volume; LVCO = left ventricular cardiac output; LGE = late gadolinium enhancement; LVEF = left ventricular ejection fraction; LVEDVI = left ventricular end-diastolic volume index; LVESVI = left ventricular end-systolic volume index; LVMI = left ventricular mass index; LVSV = left ventricular systolic volume; mPAP = mean pulmonary artery pressure; OHT-CMR = orthotropic heart transplant cardiovascular magnetic resonance imaging; PADP = pulmonary artery diastolic pressure; PASP = pulmonary artery systolic pressure; PCWP = pulmonary capillary wedge pressure; RAP = right atrial pressure; RHC = right heart catheterization; RVDP = right ventricular diastolic pressure; RVEDVI = right ventricular end-systolic volume index; RVEF = right ventricular ejection fraction; RVSP = right ventricular diastolic pressure; SD = standard deviation.